In the case of stenosis: >5 endoscopic dilatations, stent placement, or incision therapy); or fatal (death attributable to procedure <30 days or longer with continuous hospitalization).22 Statistical analysis was performed with click here a statistical software package (Statistical Package for the Social Sciences 14.0.2; SPSS Inc, Chicago, Ill). Data with a normal distribution were described with the mean and standard deviation, whereas data with a skewed distribution

were described by the median and interquartile ranges (IQR) or ranges. Confidence intervals (CI) of the proportions were calculated with Confidence Interval Analysis, version 1.0.23 Between January 2006 and October 2008, 26 consecutive patients (21 men, mean [± SD] age 66 ± 10.6 years) were included in

this study. Patient characteristics are described in Table 2. Median BE length was C9M11 cm (IQR C8-10, M10-12). None of the patients showed signs of active reflux disease, yet 13 patients (50%) were found to have reflux stenosis at the proximal this website end of the BE segment. These stenoses were generally asymptomatic and allowed passage of the therapeutic endoscopes. In 3 patients, however, endoscopic bougienage of the reflux stenosis was required before treatment to facilitate the introduction of an ER cap and RFA catheters. Eighteen patients underwent ER of visible abnormalities before RFA. The ER cap technique was used in 5 patients and multi-band mucosectomy in 13 patients. The ER specimens showed early cancer in 11 patients (intramucosal [n = 10], sm1 [n = 1], all with good or moderate differentiation and no lymphatic/vascular invasive growth), HGIN in 6 patients, and LGIN in 1 patient. Before RFA, and after ER if applicable, all patients had flat mucosa without visible abnormalities, www.selleck.co.jp/products/sorafenib.html with random mapping

biopsies showing HGIN in 16 and LGIN in 10 patients. In 2 patients (8%), the treatment protocol was discontinued because of unrelated comorbidity (psychiatric disorder and lung cancer). In both, at the last endoscopy before discontinuation, endoscopic regression of BE was 99% without histological information available. These patients were excluded from analysis of the primary endpoints. CR-neoplasia was achieved in 20 of 24 patients: 83% (95% CI, 63%-95%). CR-IM was achieved in 19 of 24 patients: 79% (95% CI, 58%-93%) (Figure 2 and Figure 3). In 4 patients (15% [95% CI, 4%-35%]), the RFA treatment was discontinued after 1 to 3 sessions because of poor healing and no or almost no regeneration of neosquamous mucosa (Fig. 4). These patients were therefore considered as failures for the primary endpoints of the study (CR-neoplasia and CR-IM). Patients achieved CR-neoplasia and CR-IM after a median of one (IQR 1-2) circumferential and two (IQR 1-3) focal ablations. Three patients underwent an escape ER for persisting BE islands after the maximum number of RFA treatments.